• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      R&R Magazine

       

      Summer 2021 Issue

      Expert Opinion

       

      Dr Martin Perry SELECT COMPARE

      Clinical Summary Videos

       

      SELECT COMPARE 

      SELECT NEXT 

      SELECT MONOTHERAPY 

      SELECT BEYOND 

      Downloadable Clinical Summaries

      SELECT COMPARE 

      View a summary of the SELECT COMPARE clinical trial - Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate.           

      SELECT MONOTHERAPY 

      View a summary of the SELECT MONOTHERAPY clinical trial - Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate.

      SELECT NEXT 

      View a summary of the SELECT NEXT clinical trial - Safety and efficacy of upadactinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs.              

      SELECT BEYOND 

      View a summary of the SELECT BEYOND clinical trial - Safety and efficacy of upadactinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs.            

      SELECT CHOICE

      View a summary of the SELECT CHOICE clinical trial - Trial of upadacitinib or abatacept in rheumatoid arthritis.           

      I want to find out more about RINVOQ

      I want to receive more information about RINVOQ

      UK-UPAD-220084. Date of preparation: March 2022

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com